Back to all MindMaze Therapeutics Holding SA press releases

MindMaze Therapeutics Holding SA

  • OTCQB:MMTZF
  • SIX:MMTX

MindMaze Announces CHF 8.0 Million Equity Financing With Neuro.io

Published

Get alerts

Plain English summaries when MindMaze Therapeutics Holding SA announces news.

At a glance

Company
MindMaze Therapeutics Holding SA
Listings
OTCQB:MMTZF, SIX:MMTX
Announcement type
Financing
Published
Source announcement
eqs-news.com
Key figures
Measure Figure Period
Equity financing CHF 8.0 million Not stated
Treasury shares 4,970,000 treasury shares this week
Second tranche CHF 4.0 million within the following five weeks
Aggregate gross cash proceeds CHF 8.0 million Not stated

Figures are quoted from this announcement and selected automatically.

FAQSIR Generated from this announcement View original release below for safe harbor and regulatory notices

Announcement Summary

MindMaze Therapeutics Holding SA (SIX: MMTX) announced a definitive equity financing with Neuro.io Group SA (Neuro.io).

  • The company expects CHF 8.0 million in aggregate gross cash proceeds; Neuro.io will acquire a strategic equity position.
  • The company expects initial CHF 4.0 million tranche to close this week: 4,970,000 treasury shares and CHF 2,850,900 mandatory convertible loan notes.
  • The company expects a second CHF 4.0 million notes tranche to close within five weeks, subject to customary closing conditions.
  • The company expects pricing today at the lower of CHF 0.23 per share and a 10% discount to average trading price.
  • The mandatory convertible loan notes are expected to convert into 29,786,521 ordinary shares within the following twelve months.

The proceeds will support commercial priorities, including scaling the U.S. footprint and advancing neurotherapeutics deployment. The parties also entered into a letter of intent to explore strategic opportunities, including a potential business combination.

Investor FAQs

MindMaze Therapeutics announced that it had entered into a definitive agreement with Neuro.io Group SA for a CHF 8.0 million equity financing. Neuro.io will acquire a strategic equity position in the Company, with proceeds intended to support commercial priorities including scaling MindMaze Therapeutics’ U.S. footprint and advancing deployment of its neurotherapeutics solutions.

Source announcement

Company
MindMaze Therapeutics Holding SA
Title
MindMaze Therapeutics Announces CHF 8.0 Million Strategic Equity Financing
Published
Source site
eqs-news.com

Read the source announcement on eqs-news.com

FAQSIR's summary and investor FAQs are generated by AI from the text of this announcement alone, without information from other sources.

Figures, forecasts and other claims are the announcement's, not FAQSIR's. FAQSIR does not independently verify them.

Read the original press release

Full text as published, unedited.

Loading the original release…